Orchid Pharma Limited has scheduled a Board meeting for August 01, 2026, to approve the allotment of fully paid-up equity shares to eligible shareholders of Dhanuka Laboratories Limited. This procedural step advances the Scheme of Amalgamation, allowing Orchid Pharma to finalize the share exchange mechanism with Dhanuka Laboratories shareholders based on their holdings as of the July 23, 2026 record date.

The company notified the National Stock Exchange of India Limited and BSE Limited on July 28, 2026, in compliance with Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation serves as a continuation of earlier disclosures made on July 10, 2026, regarding the upcoming Board proceedings.

Key Meeting Details

The Board of Directors will convene on Saturday, August 01, 2026. The primary agenda item involves the formal approval for issuing equity shares with a face value of ₹10 each. These shares are designated for distribution to Dhanuka Laboratories Limited shareholders who were recorded in the register on July 23, 2026.

Amalgamation Context

The share allotment is executed pursuant to the Scheme of Amalgamation of Dhanuka Laboratories Limited with Orchid Pharma Limited. Under this structure, Dhanuka Laboratories is identified as the "Amalgamating Company," while Orchid Pharma serves as the "Amalgamated Company." The issuance of new equity shares represents the consideration paid to Dhanuka shareholders for their stake in the merging entity.

What the Numbers Show

The fixed face value of ₹10 per equity share establishes the nominal basis for the capital expansion required to accommodate Dhanuka Laboratories shareholders. While the total number of shares to be allotted depends on the conversion ratio defined in the Scheme and the number of eligible shareholders as of July 23, 2026, the immediate impact is an increase in Orchid Pharma’s issued share capital. This dilution is structural rather than operational, reflecting the consolidation of two corporate entities into a single reporting framework under Orchid Pharma’s leadership.

Orchid Pharma Limited will conduct an investor roadshow in Singapore from July 29, 2026, to July 31, 2026. The event aims to engage with investors through physical group meetings led by Mr. Mridul Dhanuka, Whole Time Director of the company. This engagement provides institutional and retail investors with a direct channel to discuss the company’s strategic outlook and operational performance without the disclosure of unpublished price-sensitive information (UPSI).

The announcement was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The intimation was submitted to both the National Stock Exchange of India Limited and BSE Limited on July 25, 2026. Kapil Dayya, Company Secretary & Compliance Officer, signed the disclosure.

Roadshow Schedule

The investor roadshow is structured as a series of physical group meetings over three days. The specific details are as follows:

Mr. Mridul Dhanuka will represent the company throughout these sessions. The schedule remains subject to change due to unforeseen exigencies on the part of investors or the company, with any modifications to be communicated subsequently.

Compliance and Disclosure Standards

Orchid Pharma Limited explicitly stated that no Unpublished Price Sensitive Information is proposed to be shared during the investor meet. This assurance aligns with regulatory requirements to maintain market integrity and prevent insider trading risks associated with selective disclosure. The company has requested stock exchanges to take the intimation on record, ensuring transparency for all stakeholders.